Europe Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Country and Growth Forecast, 2024 - 2031
The Europe Degenerative Disc Disease Treatment Market would witness market growth of 5.2% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Degenerative Disc Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $2,917 million by 2031. The UK market is exhibiting a CAGR of 4.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 6% during (2024 - 2031).
Injections of corticosteroids into the epidural space around the affected disc can temporarily relieve pain and inflammation, particularly when conservative measures are insufficient. These injections target the small joints located between vertebrae in the spine. They can help alleviate pain originating from facet joint arthritis or dysfunction associated with DDD.
Furthermore, a surgical procedure to remove the damaged or herniated portion of a spinal disc that is pressing on nerve roots or the spinal cord. It aims to relieve nerve compression and associated symptoms such as sciatica. Fusion surgery involves permanently joining two or more vertebrae using bone grafts or synthetic materials. It stabilizes the spine and reduces pain by eliminating motion between vertebrae at the affected disc level. This procedure involves removing and replacing the damaged disc with an artificial disc device. It aims to maintain spinal motion while alleviating pain and preserving natural spine biomechanics.
Increasing patient awareness about treatment options for degenerative disc disease and efforts to improve access to healthcare services drive demand for effective therapies in Europe's market. Collaborations between research institutions, medical centers, and pharmaceutical companies in Europe contribute to developing new therapeutic approaches and medications for degenerative disc disease, expanding the market's treatment options. The economic burden of musculoskeletal disorders, including costs related to productivity loss and disability, underscores the importance of effective DDD treatments in Europe's healthcare landscape. Addressing these impacts drives investment in innovative solutions. In concision, the high prevalence of musculoskeletal disorders in Europe is driving the market's growth.
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drugs, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, Muscle Relaxants, and Steroids. Based on End Use, the market is segmented into Hospitals, Clinics, and Others. Based on Treatment Type, the market is segmented into Physical Therapy, Occupational Therapy, Special Exercises, Weight Loss Surgery, and Medications. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Medtronic PLC
- AstraZeneca PLC
- Pfizer, Inc.
- Novartis AG
- Eli Lilly And Company
- Spine Wave Inc.
- B. Braun Melsungen AG (Aesculap, Inc.)
- DiscGenics, Inc.
- Spine BioPharma Inc.
- Stryker Corporation
By Route of Administration
- Oral
- Injectable
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Acetaminophen
- Muscle Relaxants
- Steroids
- Hospitals
- Clinics
- Others
- Physical Therapy
- Occupational Therapy
- Special Exercises
- Weight Loss Surgery
- Medications
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Degenerative Disc Disease Treatment Market, by Route of Administration
- 1.4.2 Europe Degenerative Disc Disease Treatment Market, by Drugs
- 1.4.3 Europe Degenerative Disc Disease Treatment Market, by End Use
- 1.4.4 Europe Degenerative Disc Disease Treatment Market, by Treatment Type
- 1.4.5 Europe Degenerative Disc Disease Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Europe Degenerative Disc Disease Treatment Market by Route of Administration
- 4.1 Europe Oral Market by Country
- 4.2 Europe Injectable Market by Country
- Chapter 5. Europe Degenerative Disc Disease Treatment Market by Drugs
- 5.1 Europe NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
- 5.2 Europe Acetaminophen Market by Country
- 5.3 Europe Muscle Relaxants Market by Country
- 5.4 Europe Steroids Market by Country
- Chapter 6. Europe Degenerative Disc Disease Treatment Market by End Use
- 6.1 Europe Hospitals Market by Country
- 6.2 Europe Clinics Market by Country
- 6.3 Europe Others Market by Country
- Chapter 7. Europe Degenerative Disc Disease Treatment Market by Treatment Type
- 7.1 Europe Physical Therapy Market by Country
- 7.2 Europe Occupational Therapy Market by Country
- 7.3 Europe Special Exercises Market by Country
- 7.4 Europe Weight Loss Surgery Market by Country
- 7.5 Europe Medications Market by Country
- Chapter 8. Europe Degenerative Disc Disease Treatment Market by Country
- 8.1 Germany Degenerative Disc Disease Treatment Market
- 8.1.1 Germany Degenerative Disc Disease Treatment Market by Route of Administration
- 8.1.2 Germany Degenerative Disc Disease Treatment Market by Drugs
- 8.1.3 Germany Degenerative Disc Disease Treatment Market by End Use
- 8.1.4 Germany Degenerative Disc Disease Treatment Market by Treatment Type
- 8.2 UK Degenerative Disc Disease Treatment Market
- 8.2.1 UK Degenerative Disc Disease Treatment Market by Route of Administration
- 8.2.2 UK Degenerative Disc Disease Treatment Market by Drugs
- 8.2.3 UK Degenerative Disc Disease Treatment Market by End Use
- 8.2.4 UK Degenerative Disc Disease Treatment Market by Treatment Type
- 8.3 France Degenerative Disc Disease Treatment Market
- 8.3.1 France Degenerative Disc Disease Treatment Market by Route of Administration
- 8.3.2 France Degenerative Disc Disease Treatment Market by Drugs
- 8.3.3 France Degenerative Disc Disease Treatment Market by End Use
- 8.3.4 France Degenerative Disc Disease Treatment Market by Treatment Type
- 8.4 Russia Degenerative Disc Disease Treatment Market
- 8.4.1 Russia Degenerative Disc Disease Treatment Market by Route of Administration
- 8.4.2 Russia Degenerative Disc Disease Treatment Market by Drugs
- 8.4.3 Russia Degenerative Disc Disease Treatment Market by End Use
- 8.4.4 Russia Degenerative Disc Disease Treatment Market by Treatment Type
- 8.5 Spain Degenerative Disc Disease Treatment Market
- 8.5.1 Spain Degenerative Disc Disease Treatment Market by Route of Administration
- 8.5.2 Spain Degenerative Disc Disease Treatment Market by Drugs
- 8.5.3 Spain Degenerative Disc Disease Treatment Market by End Use
- 8.5.4 Spain Degenerative Disc Disease Treatment Market by Treatment Type
- 8.6 Italy Degenerative Disc Disease Treatment Market
- 8.6.1 Italy Degenerative Disc Disease Treatment Market by Route of Administration
- 8.6.2 Italy Degenerative Disc Disease Treatment Market by Drugs
- 8.6.3 Italy Degenerative Disc Disease Treatment Market by End Use
- 8.6.4 Italy Degenerative Disc Disease Treatment Market by Treatment Type
- 8.7 Rest of Europe Degenerative Disc Disease Treatment Market
- 8.7.1 Rest of Europe Degenerative Disc Disease Treatment Market by Route of Administration
- 8.7.2 Rest of Europe Degenerative Disc Disease Treatment Market by Drugs
- 8.7.3 Rest of Europe Degenerative Disc Disease Treatment Market by End Use
- 8.7.4 Rest of Europe Degenerative Disc Disease Treatment Market by Treatment Type
- Chapter 9. Company Profiles
- 9.1 Medtronic PLC
- 9.1.1 Company overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expenses
- 9.1.5 Recent strategies and developments:
- 9.1.5.1 Partnerships, Collaborations, and Agreements:
- 9.1.5.2 Trail and Approvals:
- 9.1.6 SWOT Analysis
- 9.2 AstraZeneca PLC
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
- 9.3 Pfizer, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional & Segmental Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 SWOT Analysis
- 9.4 Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 Recent strategies and developments:
- 9.4.5.1 Partnerships, Collaborations, and Agreements:
- 9.4.5.2 Acquisition and Mergers:
- 9.4.6 SWOT Analysis
- 9.5 Eli Lilly And Company
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Regional Analysis
- 9.5.4 Research & Development Expenses
- 9.5.5 SWOT Analysis
- 9.6 Spine Wave Inc.
- 9.6.1 Company Overview
- 9.7 B. Braun Melsungen AG (Aesculap, Inc.)
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expenses
- 9.7.5 SWOT Analysis
- 9.8 DiscGenics, Inc.
- 9.8.1 Company Overview
- 9.9 Spine BioPharma Inc.
- 9.9.1 Company Overview
- 9.10. Stryker Corporation
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Segmental and Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook